🚀 VC round data is live in beta, check it out!
Kyverna Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kyverna Therapeutics and similar public comparables like Kamada, Genfit, Zevra Therapeutics, Lyell Immunopharma and more.
Kyverna Therapeutics Overview
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Founded
2018
HQ
Employees
112
Website
Sectors
Financials (LTM)
EV
$342M
Kyverna Therapeutics Financials
Kyverna Therapeutics reported last 12-month revenue of — and negative EBITDA of ($173M).
In the same LTM period, Kyverna Therapeutics generated — in gross profit, ($173M) in EBITDA losses, and had net loss of ($168M).
Revenue (LTM)
Kyverna Therapeutics P&L
In the most recent fiscal year, Kyverna Therapeutics reported revenue of — and EBITDA of ($125M).
Kyverna Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($173M) | XXX | ($125M) | XXX | XXX | XXX |
| Net Profit | ($168M) | XXX | ($127M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kyverna Therapeutics Stock Performance
Kyverna Therapeutics has current market cap of $508M, and enterprise value of $342M.
Market Cap Evolution
Kyverna Therapeutics' stock price is $8.53.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $342M | $508M | 0.0% | XXX | XXX | XXX | $-2.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKyverna Therapeutics Valuation Multiples
Kyverna Therapeutics trades at (2.0x) EV/EBITDA.
EV / Revenue (LTM)
Kyverna Therapeutics Financial Valuation Multiples
As of March 18, 2026, Kyverna Therapeutics has market cap of $508M and EV of $342M.
Equity research analysts estimate Kyverna Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kyverna Therapeutics has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $508M | XXX | $508M | XXX | XXX | XXX |
| EV (current) | $342M | XXX | $342M | XXX | XXX | XXX |
| EV/EBITDA | (2.0x) | XXX | (2.7x) | XXX | XXX | XXX |
| EV/EBIT | (1.9x) | XXX | (2.4x) | XXX | XXX | XXX |
| P/E | (3.0x) | XXX | (4.0x) | XXX | XXX | XXX |
| EV/FCF | (2.3x) | XXX | (2.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kyverna Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kyverna Therapeutics Margins & Growth Rates
Kyverna Therapeutics' revenue in the last fiscal year grew by —.
Kyverna Therapeutics' revenue per employee in the last FY averaged $0.0M.
Kyverna Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 7% | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kyverna Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kamada | XXX | XXX | XXX | XXX | XXX | XXX |
| Genfit | XXX | XXX | XXX | XXX | XXX | XXX |
| Zevra Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lyell Immunopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| ADC Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kyverna Therapeutics M&A Activity
Kyverna Therapeutics acquired XXX companies to date.
Last acquisition by Kyverna Therapeutics was on XXXXXXXX, XXXXX. Kyverna Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kyverna Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKyverna Therapeutics Investment Activity
Kyverna Therapeutics invested in XXX companies to date.
Kyverna Therapeutics made its latest investment on XXXXXXXX, XXXXX. Kyverna Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kyverna Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kyverna Therapeutics
| When was Kyverna Therapeutics founded? | Kyverna Therapeutics was founded in 2018. |
| Where is Kyverna Therapeutics headquartered? | Kyverna Therapeutics is headquartered in United States. |
| How many employees does Kyverna Therapeutics have? | As of today, Kyverna Therapeutics has over 112 employees. |
| Who is the CEO of Kyverna Therapeutics? | Kyverna Therapeutics' CEO is Warner Weston Biddle. |
| Is Kyverna Therapeutics publicly listed? | Yes, Kyverna Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Kyverna Therapeutics? | Kyverna Therapeutics trades under KYTX ticker. |
| When did Kyverna Therapeutics go public? | Kyverna Therapeutics went public in 2024. |
| Who are competitors of Kyverna Therapeutics? | Kyverna Therapeutics main competitors are Kamada, Genfit, Zevra Therapeutics, Lyell Immunopharma. |
| What is the current market cap of Kyverna Therapeutics? | Kyverna Therapeutics' current market cap is $508M. |
| Is Kyverna Therapeutics profitable? | No, Kyverna Therapeutics is not profitable. |
| What is the current EBITDA of Kyverna Therapeutics? | Kyverna Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Kyverna Therapeutics? | Current EBITDA multiple of Kyverna Therapeutics is (2.0x). |
| What is the current FCF of Kyverna Therapeutics? | Kyverna Therapeutics' last 12 months FCF is ($148M). |
| What is the current EV/FCF multiple of Kyverna Therapeutics? | Current FCF multiple of Kyverna Therapeutics is (2.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.